IMV has revised its Phase Ib/II clinical trial investigating the safety and efficacy of DPX-Survivac in combination with epacadostat for the treatment of patients with recurrent ovarian cancer.

The trial examined the combination of 100mg or 300mg epacadostat and DPX-Survivac.

IMV’s revision is based on findings from the Phase Ib part of the trial that showed complete tumour regressions and disease control rate in patients treated with 100mg epacadostat.

The trial observed long duration clinical benefit in responders with a median period of 590 days, with one patient passing the two-year mark without disease progression.

“We will continue to investigate other combinations with our lead product candidate as we continue our work to deliver new immunotherapy options.”

It also revealed that the safety profile of DPX-Survivac is similar to that observed in previous studies conducted by IMV.

Based on results from the 300mg cohort, IMV has decided to stop dosing patients with epacadostat and plans to continue the trial to investigate DPX-Survivac as a monotherapy in the recurrent ovarian cancer subpopulation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

IMV CEO Frederic Ors said: “The goal of the trial was to evaluate combination therapies. However, the new data indicates that DPX-Survivac shows activity as a monotherapy in late-stage patients, which can potentially translate into clinical benefit.

“In parallel to the amended monotherapy trial, we will continue to investigate other combinations with our lead product candidate as we continue our work to deliver new immunotherapy options that may benefit more patients in multiple cancers.”

The company intends to meet US Food and Drug Administration (FDA) representatives in December to present results related to the subpopulation of the Phase Ib/II study.